Heart Lung and Circulation心脏、肺与循环
Heart Lung and Circulation(英文缩写 HEART LUNG CIRC),ISSN 1443-9506,eISSN 1444-2892,中文译名:心脏、肺与循环 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-09-28 至 2026-09-28，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 2.838 | Q3 |
| 2022 | 2.600 | Q3 |
| 2023 | 2.200 | Q2 |
| 2024 | 2.200 | Q2 |
| 2025 | 2.500 | Q2 |
Heart Lung and Circulation 最新收录文献
-
1. Administration of Enoximone for the Optimisation of Renal Function in Cardiac Surgery: Final Results of a Multicentre Study.
PMID:日期:2026-09-22Postoperative renal failure remains a major determinant of morbidity and mortality after cardiac surgery, with limited preventive pharmacological options. Enoximone, a phosphodiesterase III inhibitor with inotropic and anti-inflammatory properties, has shown potential for organ protection during cardiopulmonary bypass. We aimed to evaluate the effect of perioperative enoximone administration on renal function and clinical outcomes in patients undergoing on-pump cardiac surgery. This multicentre prospective observational study included adult patients undergoing on-pump cardiac surgery. Patients with severe preoperative kidney failure were excluded. Renal function was assessed at postoperative days 2, 7, and 30 using estimated glomerular filtration rate (eGFR) and Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) stage. Perioperative administration of enoximone was compared with untreated controls using propensity score matching. A total of 237 patients were included, of whom 110 (46.4%) received enoximone. After matching, 72 treated patients were compared with 72 controls. No differences in eGFR were observed at day 2 and day 7. At day 30, enoximone was associated with greater eGFR improvement (+8.1 vs -3.7 mL/min/1.73 m; p<0.001). CKD-EPI stage improved in the Enoximone-treated group at day 7 (-0.3±0.6; p=0.037) and day 30 (-0.3±0.5; p<0.001). Enoximone was an independent predictor of 30-day eGFR improvement (β=+10.65; p<0.001) and CKD-EPI reduction (β=-0.26; p=0.002). Enoximone was also associated with reduced use of additional inotropes (4.2% vs 26.4%; p<0.001) and shorter hospital stay (13.2±7.2 vs 17.1±10.5 days; p=0.008). Perioperative enoximone administration was associated with improved renal function and reduced hospital length of stay in patients undergoing on-pump cardiac surgery. These findings support its potential role in preventing postoperative renal failure. Further studies are warranted to confirm these results.
-
2. Cardiovascular Risk, Comorbidity and Frailty in Patients Undergoing Sleeve Gastrectomy: A Population-Based Study.
PMID:日期:2026-09-18Cardiometabolic conditions and frailty influence perioperative risk in bariatric surgery; however, contemporary population-level studies describing these factors are limited. This study characterised the cardiometabolic burden, comorbidity, and frailty of adults undergoing laparoscopic sleeve gastrectomy (LSG), with comparisons according to sex and hospital setting. A population-based cohort study was conducted using statewide administrative hospital data from all public and private hospitals in New South Wales, Australia, between 1 July 2017 and 30 June 2022. Adults (≥18 years) undergoing primary LSG were included. The prevalence of cardiometabolic comorbidities and trends in age-adjusted disease rates were assessed. Subgroup analyses according to sex and hospital setting were performed for cardiovascular risk factors, comorbidity, and frailty. Among 34,738 patients (78.3% female; 96.6% treated in private hospitals; mean age 41.3±11.5 years), nearly three-quarters (72.3%, n=25,130) had one or more cardiovascular risk factors. The prevalence of type 2 diabetes mellitus (T2DM) declined by 24.4% (148.8-112.5 per 1,000; p<0.001). Males had a higher cardiovascular risk burden (44.3% vs 28.0% with ≥2 risk factors; p<0.001), greater comorbidity burden (Elixhauser index: 1.35 vs 1.07; p<0.001), and higher frailty scores (Claims Frailty Index: 0.12 vs 0.11; p<0.001). Public hospital patients, particularly males, had the highest burden across all measures. There was substantial variation in cardiometabolic burden among LSG recipients according to sex and hospital sector. The observed decline in T2DM suggests a change in the clinical profile of patients undergoing surgery. These findings warrant further investigation into the factors influencing access to surgery and patient selection.
-
3. Atrial Septal Aneurysm Complicated With an Intracardiac Thrombus in a Neonate: A Rare Presentation.
PMID:日期:2026-09-18该文献暂无摘要。
-
5. Transcatheter Aortic-Valve Implantation for Native-Valve Infective Endocarditis.
PMID:日期:2026-09-18该文献暂无摘要。
-
7. Achieving ≥90% of the Age-Predicted Treadmill Time for Commercial Vehicle Operation Does Not Predict Future Cardiovascular Events.
PMID:日期:2026-09-18Functional capacity (FC) has been shown to be a strong independent predictor of all-cause and cardiovascular (CV) mortality. Nomograms based on age and sex have been developed to standardise exercise times and FC during treadmill testing (TT). Many patients with prior CV disease perform TT as a requirement for commercial vehicle operation. The current recommendations state a level ≥90% of FC for age should be achieved during testing. Whether this level predicts future CV outcomes is not known. Maximal exercise stress echocardiography was performed on 196 patients with prior treated CV disease for the assessment of returning to commercial vehicle operation. Patients were followed for 5.8±2.4 years with future CV events as the outcome variable. There were 55 patients with a CV event during the census period. No significant differences were found between those with and without a CV event regarding medication use, CV risk factors or TT data. Cox proportional hazards analysis revealed only statin use (HR 0.49 (0.01-0.91); p=0.02) and inability to reach a maximal rate pressure product (MRPP) of 25,020 (HR 2.81 (1.6-5.0); p<0.001) as independent predictors of CV events, with MRPP the only multivariate predictor (HR 2.5 (1.01-6.28); p=0.04). Achieving an age-predicted FC ≥90% following maximal TT does not predict CV outcome (p=0.536) in patients with previous CV disease being assessed for commercial vehicle operation. Inability to reach an MRPP of 25,020 was a strong predictor of future CV events.
-
8. Short-Term Clinical Outcomes After Percutaneous Coronary Intervention Among Culturally and Linguistically Diverse (CALD) Patients in Australia.
PMID:日期:2026-09-18We aimed to evaluate the effect of culturally and linguistically diverse (CALD) status on clinical outcome as measured by 30-day major adverse cardiac and cerebrovascular events (MACCE) after percutaneous coronary intervention (PCI). This observational cohort study involved analysis of data from a high-volume tertiary centre in Melbourne, Australia. Adults who underwent PCI at a tertiary health service in Melbourne, Australia (January 2014-December 2021), were stratified into CALD (those born in non-English-speaking countries and/or whose primary language at home is not English) and non-CALD status. The main outcome measures were in-hospital and 30-day MACCE (composite of new heart failure, myocardial infarction, stent thrombosis, major bleeding, stroke, rehospitalisation, and mortality). Compared to non-CALD (n=3,301, 51%), CALD patients (n=3,112, 49%) were older (mean age 65.2 vs. 61.5 years), more likely to be on medication for type 2 diabetes mellitus (33.5% vs 21.7%), had prior coronary artery bypass grafting (5.5% vs 3.7%) and were on dialysis (2.2% vs 1.0%; all p<0.001). CALD patients presented less frequently with acute coronary syndromes (58.7% vs 65.8%; p<0.001) but had increased rates of multivessel disease (8.9% vs 6.9%; p=0.004). In the ST-elevation myocardial infarction subgroup, CALD patients had lower pre-hospital notification rates (13.1% vs 20.7%) and longer symptom to PCI time (599 vs 420 minutes; both p<0.001). At 30 days, CALD patients had higher rates of rehospitalisation (13.9% vs 11.9%) and major bleeding (0.5% vs 0.1%; both p=0.05) but not overall MACCE (5.0 vs. 5.9%; p=0.12) or mortality (2.8% vs. 3.3%; p=0.28). Despite higher rates of co-morbidities, re-hospitalisation and major bleeding, CALD patients had comparable 30-day mortality compared to non-CALD patients in contemporary systems of care. These data suggest that evolving changes within care network tailored to CALD patient needs might be beneficial and require further prospective studies.
-
9. Recent Trends in Genetic Testing for Familial Hypercholesterolaemia in Australia.
PMID:日期:2026-09-14该文献暂无摘要。
-
10. Pulsed Field Ablation for Atrial Fibrillation in Australia: A Large Tertiary Centre Analysis.
PMID:日期:2026-09-10Pulsed field ablation (PFA) is increasingly used for catheter ablation of atrial fibrillation (AF). Limited real-world data exists regarding safety and efficacy of PFA in Australia. We conducted a retrospective analysis of consecutive patients undergoing de novo PFA for paroxysmal or persistent AF at a large tertiary centre using a pentaspline catheter (FARAPULSE, Boston Scientific) from 2022 to 2025. Baseline demographics, procedural characteristics, procedural complications, clinical outcomes and repeat procedures were collected. Arrhythmia recurrence was defined as >30 seconds of AF, atrial flutter or atrial tachycardia at follow-up with no blanking period. Overall, 564 consecutive patients (median age 64 years, 35% female) underwent de novo PFA for AF during the study period. Most patients had paroxysmal AF (63%). Pulmonary vein (PV) isolation was performed in 563 of 564 patients; posterior wall (PW) isolation was performed in 41% and superior vena cava ablation in 3%. Median total applications were 58 (interquartile range [IQR] 50-70). Median total procedural time was 63 minutes (IQR 51-76). Major procedural complications occurred in 1.8% (10/564) patients and minor procedural complications occurred in 12.6% (71/564), mostly because of minor vascular access complications (8.2%). Six (6)-month freedom from arrhythmia was 72%; cardioversions were performed in 5.3% and 2.7% had arrhythmia-related hospitalisation. In 35 patients (6.2%) who underwent repeat procedure, PV and PW durability was 45% and 32%, respectively. PFA for AF is reasonably safe with acceptable clinical outcomes. These real-world data provide clinicians with potential expected clinical outcomes for patients referred for PFA in Australia.